ReviewGut microbes2026
Gut microbiota: a novel key player in urinary stone formation - from oxalate metabolism to systemic regulation.
Review in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney stones represent a globally prevalent disease with a rising incidence associated with multiple factors, including obesity and metabolic syndrome. While traditional research has primarily focused on dietary nutrition and metabolic abnormalities, recent years have seen growing recognition of the gut microbiota as a key novel regulator in stone formation. Accumulating cross-sectional evidence suggests that kidney stone patients are often associated with alterations in gut microbiota composition and function compared with healthy individuals. The gut microbiota may influence kidney stone formation risk through multiple potential mechanisms, including affecting oxalate metabolism, calcium-phosphorus absorption, short-chain fatty acid and bile acid pathways, and regulating systemic inflammatory and immune states. More importantly, this "gut-kidney axis" function of the gut microbiota holds clinical translational potential, suggesting that targeted microbial interventions may emerge as novel strategies for preventing and treating kidney stones. This review explores the association between gut microbiota and kidney stones, discussing clinical evidence, underlying mechanisms, and intervention strategies while analyzing current challenges and outlining future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.